Terms: = Breast cancer AND HER1, YOR227W AND Prognosis
57 results:
1. [Application of neratinib in the treatment of hormone receptor and HER-2 double positive breast cancer].
Wang X; Yuan P
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):511-515. PubMed ID: 34034468
[TBL] [Abstract] [Full Text] [Related]
2. Neratinib in the early-stage/extended adjuvant breast cancer patient.
O'Shaughnessy JA; Isaacs C; O'Regan R
Clin Adv Hematol Oncol; 2020 Aug; 18 Suppl 12(8):1-20. PubMed ID: 33843843
[TBL] [Abstract] [Full Text] [Related]
3. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
4. Quantification of her1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Ho-Pun-Cheung A; Bazin H; Boissière-Michot F; Mollevi C; Simony-Lafontaine J; Landas E; Bleuse JP; Chardès T; Prost JF; Pèlegrin A; Jacot W; Mathis G; Lopez-Crapez E
Br J Cancer; 2020 Feb; 122(3):397-404. PubMed ID: 31792349
[TBL] [Abstract] [Full Text] [Related]
5. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
Maisel SA; Broka D; Atwell B; Bunch T; Kupp R; Singh SK; Mehta S; Schroeder J
J Transl Med; 2019 Jun; 17(1):201. PubMed ID: 31215437
[TBL] [Abstract] [Full Text] [Related]
6. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract] [Full Text] [Related]
7. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
8. Piperlongumine downregulates the expression of HER family in breast cancer cells.
Jin HO; Park JA; Kim HA; Chang YH; Hong YJ; Park IC; Lee JK
Biochem Biophys Res Commun; 2017 May; 486(4):1083-1089. PubMed ID: 28377224
[TBL] [Abstract] [Full Text] [Related]
9. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract] [Full Text] [Related]
10. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes?
Göksu SS; Bozcuk H; Koral L; Çakar B; Gündüz S; Tatlı AM; Arslan D; Uysal M; Koçer M; Artaç M; Karabulut B; Coşkun HS; Özdoğan M; Savaş B
Indian J Cancer; 2015; 52(4):517-9. PubMed ID: 26960462
[TBL] [Abstract] [Full Text] [Related]
11. HER family receptor expression and prognosis in pancreatic cancer.
Bittoni A; Mandolesi A; Andrikou K; Santoni M; Alfonsi S; Lanese A; Loretelli C; Pellei C; Piva F; Scarpelli M; Cascinu S
Int J Biol Markers; 2015 Jul; 30(3):e327-32. PubMed ID: 26109364
[TBL] [Abstract] [Full Text] [Related]
12. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.
Templeton AJ; Diez-Gonzalez L; Ace O; Vera-Badillo F; Seruga B; Jordán J; Amir E; Pandiella A; Ocaña A
Cancer Treat Rev; 2014 Oct; 40(9):1048-55. PubMed ID: 25217796
[TBL] [Abstract] [Full Text] [Related]
14. [Carcinosarcoma of the breast a rare entity with fatal prognosis. One case report].
Villalón-López JS; Souto-del Bosque R; Alonso-Briones MV; Trujillo-de Anda AP
Cir Cir; 2013; 81(4):328-32. PubMed ID: 25063898
[TBL] [Abstract] [Full Text] [Related]
15. Lapatinib.
Nolting M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2014; 201():125-43. PubMed ID: 24756789
[TBL] [Abstract] [Full Text] [Related]
16. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract] [Full Text] [Related]
17. The function of human epidermal growth factor receptor-3 and its role in tumors (Review).
Li Q; Yuan Z; Cao B
Oncol Rep; 2013 Dec; 30(6):2563-70. PubMed ID: 24084886
[TBL] [Abstract] [Full Text] [Related]
18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract] [Full Text] [Related]
19. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Larsen MS; Bjerre K; Lykkesfeldt AE; Giobbie-Hurder A; Laenkholm AV; Henriksen KL; Ejlertsen B; Rasmussen BB
Breast; 2012 Oct; 21(5):662-8. PubMed ID: 22854050
[TBL] [Abstract] [Full Text] [Related]
20. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract] [Full Text] [Related]
[Next]
